role of dose-intensive chemotherapy in the treatment of chemotherapy-sensitive malignancies. 1 Multiple myeloma is one example in which a clinical relationship between Attempts to increase dose intensity have been hampered by hematologic toxicity. To address this issue, we dose intensity of melphalan and response rate has been demonstrated. 2 Unfortunately, melphalan dose escalation is designed a study to determine whether the reinfusion of PBPC significantly reduces the toxicity of multicyclic limited by myelosuppression, and only a modest increase in dose intensity can be achieved with the administration dose-intensive chemotherapy. Thirty refractory patients, median age 63, received CY 3 g/m 2 plus of hemopoietic growth factors.
3,4
Administration of G-CSF following chemotherapy leads melphalan 60 mg/m 2 followed by PBPC and G-CSF (CM regimen). CY (at day 0) and G-CSF were used to to the release of a large number of PBPC, 5-7 whose quality is equivalent to that of bone marrow. 8 The infusion of mobilize PBPC harvested by a single leukapheresis at day 10. Melphalan was infused at day 11. PBPC were PBPC results in a considerable increase in dose intensity. 4, 6 Sufficient PBPC for transplantation can be obtained at a kept unprocessed at 4؇C for 48 h and reinfused at day 12. This regimen was repeated three times every 6 single leukapheresis. 9 Whole blood and leukapheresis products remain viable for several days at 4°C. 10 This has led months. Outcomes were compared with those of 30 similar patients treated with melphalan 30 mg/m 2 folus to investigate the use of non-cryopreserved PBPC to support dose-intensive chemotherapy in elderly myeloma lowed by G-CSF only, and repeated every 2 months for a total of six cycles. In patients receiving CY plus patients.
The significance of dose intensity is evident in refractory melphalan followed by PBPC reinfusion, the median duration of neutropenia (ANC Ͻ500/l) and thrommyeloma patients. Oral melphalan and prednisone induced an unsatisfactory response rate of 20%. 11, 12 Intravenous bocytopenia (platelets Ͻ25 000/l) was only 5 and 2 days respectively, and did not increase after the submelphalan 25 mg/m 2 increased responses to 35%. 13 Melphalan 50 to 100 mg/m 2 resulted in a 50-60% response rate. sequent courses. Hematologic toxicity was quite similar to that observed after melphalan 30 mg/m 2 plus G-CSF. A median of 4 weeks was needed for hematological recovery, despite the use of hemopoietic growth factors. 14 In a The CM regimen was followed by 30% complete remission and 86% response Ͼ50%, melphalan recent experience, melphalan 70 mg/m 2 combined with G-CSF induced a prolonged myelosuppression in 10 pre-30 mg/m 2 by no complete remissions and 38% response Ͼ50%. Patients receiving CM regimen showed a longer viously treated multiple myeloma patients: granulocytes remained Ͻ500/l for a median of 20 days (range 11-36) progression-free survival (22 vs 10 months, P Ͻ 0.01). The dose intensity of melphalan can be doubled by and platelets Ͻ25 000/l for a median of 16 days (range 5-59).
15
Melphalan 140-200 mg/m 2 further increased reinfusing PBPC without increasing toxicity. The combination of CY and melphalan followed by PBPC response rate to 75-85%, a median of 2 weeks was required for hematological recovery when PBPC were employed. Thirty refactory myeloma patients entered the protocol
24
between December 1992 and September 1995 and received CY 3 g/m 2 ϩ melphalan 60 mg/m 2 followed by PBPC and G-CSF. The SWOG diagnostic criteria 22 and Durie and Salmon 23 staging system were used. Six were resistant to melphalan and 12 to doxorubicin and dexamethasone-containthan 500/l in two consecutive tests. The CM regimen was ing regimens at diagnosis (primary resistance); three were repeated every 6 months for a total of three cycles. resistant to doxorubicin and dexamethasone at relapse (resistant relapse); nine initially responding patients had Melphalan ϩ G-CSF: Control patients received i.v. melrelapsed after melphalan (three) or doxorubicin and phalan at 30 mg/m 2 at day 0, and G-CSF (5 g/kg) s.c. dexamethasone (six) (relapse). Inclusion criteria were: age from day 3 until the ANC was greater than 500/l in two Ͼ55 and Ͻ70, serum creatine Ͻ3 mg/dl, normal cardiac consecutive tests. The infusion was repeated every 2 and pulmonary functions.
months for a total of six cycles. Thirty historical control patients were identified who were resistant or relapsed to the same therapies and met the elegibility criteria for the CM regimen. Six were resistant
Monitoring PBPC mobilization to melphalan and 10 to doxorubicin and dexamethasoneBlood counts were performed before CY and then every containing regimens at diagnosis (primary resistance); four other day until harvest. The percentage of circulating were resistant to doxorubicin and dexamethasone at relapse CD34 ϩ cells was evaluated as previously descibed. 24, 25 To (resistant relapse); 10 initially responding patients had evaluate granulocyte-macrophage colony formation (CFUrelapsed after melphalan (four) or doxorubicin and dexame-GM), leukapheresis samples were diluted 1:50 in IMDM thasone (six) (relapse). Five patients refused the CM regisupplemented with 10% FCS (Flow Laboratories, Irvine, men, The remainder received low-dose melphalan during UK), then volumes of 10, 20 and 100 l were seeded in the 2 years before activation of the protocol. All were duplicate in 1-ml mixtures containing IMDM supplemented treated with melphalan 30 mg/m 2 followed by G-CSF with 20% FCS, 10% conditioned medium obtained from only. Patient characteristics are listed in Table 1. the 5637 cell line (5637-CM) as a source of growth factors, and 0.3% agar. Colonies were counted after 14 days incuTreatment regimens bation at 37°C in a 5% CO 2 and 5% O 2 atmosphere.
CY-Melphalan (CM) regimen ϩ PBPC:
The schema of the CM regimen is shown in Figure 1 . CY 3 g/m 2 was given at Leukapheresis and PBPC storage day 0 in two doses with subsequent i.v. MESNA 3 g/m 2 in five divided doses. Urine was closely monitored to detect PBPC were collected with a Fresenius Cell Separator AS 104 (MTS, Schweinfurt, Germany). A single leukapheresis hemoglobinuria on days 0-3. The infusions were performed on an outpatient basis over a 10 h period. The CY was performed on day 10, over a 4 h period through a double peripheral venous access. The blood volume processed dose was chosen to guarantee transient neutropenia without thrombocytopenia. G-CSF was administered at ranged from 8.5 to 12 l. Leukapheresis collections (volume range: 450-600 ml) were kept at 4°C for 48 h. Immediately 10 g/kg/day s.c. from days 3 to 9. At day 10, a single leukapheresis was performed and its product was kept at before reinfusion, the volume was reduced to approximately 250 ml by centrifugation. To evaluate the effect of 4°C for 48 h without further processing. At day 11, melphalan 60 mg/m 2 was infused in 30 min. At day 12, PBPC storage temperature on cell viability, two samples from the first 10 leukephereses were kept at 4°C and 18°C for 96 h. were reinfused over a 2 h period. G-CSF was administered at 5 g/kg/day s.c. from day 14 until the ANC was greater CD34 + analysis and CFU-GM assay were performed daily. 
Response criteria and statistics
Patients with fever Ͼ38°C 3 0 2 7 Patients hospitalized 20 27 Response Ͼ50% was defined as 50% reduction of serum myeloma protein, 75% decrease of Bence-Jones proteinuria
and 50% reduction of bone marrow infiltration. Response Ͼ75% was defined as 75% reduction of serum myeloma protein, no Bence-Jones proteinuria on urine electrophoresis and marrow plasmacytosis Ͻ5%. Complete remission required disappearance of serum myeloma protein by immunofixation, no Bence-Jones proteinuria and marrow plasmacytosis Ͻ1% for at least 2 months. All other results were regarded as failures. Statistical methods included 2 tests for comparison of rates 26 and KaplanMeier estimates. 27 Progress-free survival curves were plot- 
CY treatment and mobilization regimen
After CY infusion the nadir was reached at day 7 or 8 when CM regimen: comparison with melphalan 30 mg/m 2 the median WBC and ANC counts were 2100/l and ϩ G-CSF during the first course (Table 2 ) 510/l, respectively. Before melphalan administration they Effect on neutropenia: In patients receiving PBPC, neutrowere 5500/l and 3100/l, respectively. Platelets were phil levels always fell below 100/l after a median of 8 never Ͻ100 000/l. No patient required hospitalization days (range 7-10), followed by recovery to 500/l after a after CY therapy; gross hematuria was never detected, median of 13 days (range 11-16). The median duration of despite the single-day infusion; 23% of patients experisevere neutropenia (ANC Ͻ 500/l) was similar when CYenced asymptomatic microscopic hematuria. melphalan ϩ PBPC was compared with melphalan ϩ G-CD34 ϩ cell peak occurred in 13% of patients on day 9, CSF: 5 days (range 2-9) vs 4 days (range 0-9). Criteria for in 60% on day 10, in 27% on day 11. On day 10, the dose-limiting neutropenic toxicity, defined as more than 7 median levels of WBC and absolute CD34 ϩ cells were days of grade 4 neutropenia (ANC Ͻ 500/l), were 13.3 ϫ 10 9 /l (range 0.84-49) and 29.9 ϫ 10 6 /l (range 6.2-met in 23% of those treated with CY-melphalan ϩ PBPC, 229), respectively. The percentage of CD34 ϩ cells was usucompared with 26% of patients treated with melphalan ϩ ally higher on day 9. However, the absolute number of G-CSF. CD34 ϩ cells increased on day 10 as a result of leukocytosis.
Effect on thrombocytopenia:
In patients receiving PBPC, PBPC storage platelets fell below 25 000/l in 70% of patients after a median of 12 days (range 10-13). The median duration of Leukapheresis products were kept unprocessed at 4°C before reinfusion. The effects of storage temperature on the severe thrombocytopenia (platelets Ͻ 25 000/l) was similar when CY-melphalan ϩ PBPC was compared with melviability of hemopoietic progenitors were determined (Figure 2 ). Storage at 4°C resulted in a slight CFU-GM loss phalan ϩ G-CSF: 2 days (range 0-7) vs 2 days (range 0-5). Dose-limiting thrombocytopenia, defined as more than after 48 h (range 5-15%) and a notable loss after 72 h (range 10-50%). CD34 ϩ cell concentrations remained 7 days of platelets Ͻ 25 000/l, occurred in 7% of patients treated with CY-melphalan ϩ PBPC, and in 10% of those stable for 96 h. By contrast, storage at 18°C resulted in a significant CFU-GM and CD34
ϩ cell loss after 48 h. treated with melphalan ϩ G-CSF.
courses. Despite this decline, all patients were treated without a significant increase of the hematologic toxicity. The median duration of neutropenia and thrombocytopenia, transfusion requirement, incidence of fever and hospitalization were unchanged after the subsequent courses (Table 3) . Among patients treated with melphalan 30 mg/m 2 , all patients were eligible for the first course, 25 for the third, and 13 for the sixth course. Exclusions were mainly related to progressive disease despite treatment. Hematologic toxicity did not change significantly after subsequent courses, even though a cumulative thrombocytopenia was observed.
The CM regimen was well tolerated. There was no complication related to leukapheresis, apart from occasional lip paresthesia, caused by hypocalcemia and promptly abolished with i.v. calcium gluconate. All melphalan chemotherapy and PBPC reinfusions were administered in an outpatient setting. Non-cryopreserved PBPC reinfusion was completely asymptomatic due to the lack of cellular aggregates. A Pneumocystis carinii pneumonia was the major instance of toxicity. This episode prompted us to switch from ciprofloxacin to cotrimoxazole prophylaxis during the neutropenic period.
Tumor response
On an intention to treat basis, the CM regimen induced 30% complete remissions, 53% responses Ͼ75%, and 86% (Table 4) . After the first, second and third course products. Two samples from 10 leukaphereses were stored at 4°C and responses Ͼ50% were 63%, 85% and 86%, complete
18°C. GM-CFU (--4°C, ---18°C) and CD34
ϩ cell viability (--remissions 13%, 23% and 30%, respectively. Performance of bone pain. After chemotherapy, it improved significantly in eight patients, who discontinued analgesic treatment and were able to perform their normal daily activities. By conTransfusion requirement: The CM regimen combined the infusion of both CY and melphalan within 11 days, while trast, melphalan 30 mg/m 2 induced no complete remission, 8% responses Ͼ75% and 38% Ͼ50%. the control group received melphalan only. Despite these differences, the median number of RBC (1 vs 0) and platelet transfusions (1 vs 1), and the percentage of patients Survival requiring RBC (57% vs 40%) and platelet support (53% vs 53%), was similar for both groups.
After a median follow-up of 20.3 months (range 5-29), 21 patients were alive with a median actuarial progression-free survival of 22 months and overall survival not reached for Extra-hematologic toxicity: Twenty percent of patients receiving melphalan ϩ PBPC were hospitalized: one for patients treated with the CM regimen. After a median follow-up of 14.6 months (range 2-50), eight patients were pneumonia, three for fever of unknown origin, one for necrotizing fasciitis, and one for mucositis and diarrhea. By alive with a median actuarial progression-free survival of 10 months and overall survival of 13 months for patients contrast, 27% of patients treated with melphalan ϩ G-CSF were hospitalized: one for septicemia, one for pneumonia, treated with melphalan 30 mg/m 2 . Progression-free survival was significantly different between the two groups two for fever of unknown origin, one for mucositis, one for gastrointestinal toxicity, one for kidney failure, and one (P Ͻ 0.01) and was probably related to the difference in response rate (Figure 3) . Non-responsive patients showed a for transfusion requirement.
poor outcome in both groups (data not shown).
CM regimen: comparison with melphalan 30 mg/m 2 ϩ G-CSF during subsequent courses
Discussion All patients were eligible for the first course, 26 for the second course (one exclusion for progression, three for Advances in the use of cytokines and PBPC support have drastically changed the chemotherapy approach to cancer CD34 ϩ harvest Ͻ0.5 ϫ 10 6 /kg), and 21 for the third course (five exclusions for relapse) of the CM regimen. The patients, allowing both dose intensification and myelotoxicity reduction. The use of hemopoietic growth factors has median number of CD34 ϩ cells reinfused was reduced from 2.8 to 2 to 1.5 ϫ 10 6 /kg after the first, second and third resulted in a significant improvement in neutropenia after without any increase in hematologic toxicity and care requirements. 29 Here, we show that the dose intensity of melphalan can be doubled by using PBPC without any conventional chemotherapy. 25 However, further dose intenchange in hematologic toxicity. Reduction of grade 4 hemasification has been limited by thrombocytopenia and cumutologic toxicity to less than a week was essential to reduce lative myelotoxicity. In a randomized trial, G-CSF hospital stay. Only strategies inducing grade 4 hematologic increased the dose intensity of cytotoxic chemotherapy by toxicity Ͻ7 days may be feasible to increase dose intensity only 12% when compared with control patients, and did in conventional outpatient chemotherapy practice. not result in significant differences in drug toxicity, other
Mobilization of an adequate number of PBPC is mandathan neutropenia. expenses. CY 1.5 g/m 2 efficiently mobilizes PBPC, while tures our data are not conclusive and a randomized study is warranted. increasing doses enhance their number proportionally.
7 CY 7 g/m 2 is the optimal regimen, 7,30,31 but infections and longIn summary, this novel approach demonstrates the feasibility of using PBPC to administer dose-intensive mellasting thrombocytopenia requiring platelet support are predictable in elderly patients. We first chose 2 g/m 2 phalan with a simplified approach and low toxicity. The delivery of repetitive, spaced courses is likely to improve (unpublished data). Since this dose was well tolerated, we moved to 3 g/m 2 . Despite this increase, no patient required response rate and clinical outcome. More importantly, the data reported here are sufficiently encouraging to warrant hospitalization or transfusion support. Some authors have found frequent complications with CY 4 g/m 2 . 32 Thus, further attempts to improve this therapeutic modality. 3 g/m 2 seems the maximum tolerated dose for an outpatient regimen designed to require health care support similar to conventional chemotherapy. To make up for the use of Acknowledgements a suboptimal CY dose, G-CSF was increased to 10 g/kg/day, since previous reports indicate a dose- PBPC were stored for 48 h at 4°C. We evaluated the possibility of their longer storage at 4°C and 18°C, since previous reports had suggested storage at room temperature. 34 Significant CFU-GM progenitor loss appeared after References 72 h at 4°C and after 48 h at 18°C, compared with only 5-15% after 48 h at 4°C. Freeze-thawing kills at least 20- phalan. Although patients showed comparable clinical fea-
